Despite these intriguing findings in the immune system, there is a paucity of studies relating NRF2 activation and anti-inflammatory activity in cancer cells, which is important since cancers with KEAP1 mutations are resistant to immune checkpoint inhibition [20]. The gene discussed is KEAP1; the disease is cancer.